Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

NCT03656562 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG: VAY736
DRUG: VAY736 Placebo
DRUG: CFZ533
DRUG: CFZ533 Placebo

Sponsor

Novartis Pharmaceuticals